NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Updated: Feb 6
NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Sponsor
Locations
United States, California
United States, Minnesota
ClinicalTrials.gov Identifier: NCT05227144
Official Title: An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : February 7, 2022
Click here for details on ClinicalTrials.Gov
Drug: ORIC-533
CD73 Inhibitor ORIC-533 (Code C185560)
CD73 Inhibitor ORIC-533
ORIC 533
ORIC-533
ORIC533
Location
United States, California
United States, Minnesota